AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02304536 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian drilling
Description: 70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
Study NCT01094717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin 25Mg Oral Capsule
Description: Acitretin 25 mg oral daily for 12 weeks
Study NCT01094717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser
Description: Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.
Study NCT01094717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% Gel,Top
Description: Topical tazarotene 0.1% gel was applied daily to active lesions.
Study NCT01094717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham excimer laser
Description: Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
Study NCT03229915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive processing therapy
Description: Group therapy for PTSD patients
Study NCT04263337 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [11C] PiB
Description: Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Study NCT04113889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)
Description: 72 patients with PCOS receiving metformin, pioglitazone and Acetyl L-Carnitine 500 mg, 15 mg and 1.5 gm BD daily respectively.
Study NCT04113889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin, pioglitazone and placebo
Description: 72 patients with PCOS receiving metformin, pioglitazone and placebo 500 mg, 15 mg and placebo BD daily respectively.
Study NCT04159259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fiber diet
Description: Participants will be provided with a low fiber diet in the form of packed out meals and snacks for 24 days in total (days 5-14 and days 36-49)
Study NCT04159259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea Fiber Bar
Description: Participants will be provided with a low fiber diet plus 1-3 daily pea fiber bars from days 15-35
Study NCT04159259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fiber diet
Description: Participants will return to the low fiber diet for days 36-49- this phase is the same as phase 1.
Study NCT02332668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT01733316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP103
Study NCT01733316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cystagon®
Study NCT03782961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sodium lactate and combination of polymers
Description: sodium lactate and combination of polymers (polycarbophil, carbomer and PVM / MA copolymer)
Study NCT04663204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sparsentan
Description: Target dose of 400 mg daily
Study NCT03334630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiamondTemp Ablation catheter
Description: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
Study NCT03334630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TactiCath Quartz Ablation catheter
Description: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
Study NCT02460458 — intervention group
Intervention type: DRUG
Intervention: Von Willebrand Factor
Description: Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.
Study NCT02059408 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screen-Educate
Description: Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm will recommend using creatinine, cystatin C and albuminuria for screening and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage. Recommendations are sent to the primary care provider via an electronic note.
Study NCT02059408 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screen-Educate and Intensify Treatment
Description: This arm adds option of a pharmacist. PCPs randomized to this arm will have the additional option to refer their higher-risk patients to a clinical pharmacist-led CKD management program with education. A primary care clinical pharmacist will schedule a series of appointments with patients found to have confirmed higher-risk CKD (defined as eGFRcreat-cys \<45, or eGFR 45-59 and ACR ≥ 30 mg/g). The pharmacist will follow treatment algorithms recommended by the 2012 KDIGO international CKD guidelines, and designed by a team of internists and nephrologists.
Study NCT04690933 — intervention group
Intervention type: OTHER
Intervention: Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients
Description: Signing of consent at the time of the pre-transplant consultation (1 month before grafting). Inclusion of patients during conditioning (around D-8 of transplantation). Samples related to the cohort:one blood sample from the donor (only familial donors) for genetic SNPs analysis. 5 samples: D-8, D20, D100, D200 (+/-10 days), 1 year : 1 tube of 7ml of whole blood on EDTA: Biobanking of whole blood for genetic SNPs analysis (D-8) of specific transporters for GCV, and of plasma for TTV viral load at all times. In routine care:samples taken in the event of a therapeutic escape (2 x 7 ml EDTA tubes, for resistance genotype, and ganciclovir dosage, 3 x 1 ml for Quantiferon CMV, according to CNR Herpesvirus recommendations. 1 x Paxgene tube (2.5 ml) for subsequent CMV genomic and transcriptomic studies. Cell preservation plasma and whole blood for biocollection (2 tubes EDTA de 7ml). Samples stored by the centers' virology laboratories are periodically sent to the CNR for analysis.
Study NCT02626533 — intervention group
Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Patients will undergo total unilateral knee arthroplasty for osteoarthritis.
Study NCT03602508 — intervention group
Intervention type: DRUG
Intervention: mirabegron
Description: oral
Study NCT03602508 — intervention group
Intervention type: DRUG
Intervention: solifenacin
Description: oral
Study NCT03602508 — intervention group
Intervention type: DRUG
Intervention: darifenacin
Description: oral
Study NCT03602508 — intervention group
Intervention type: DRUG
Intervention: imidafenacin
Description: oral
Study NCT03602508 — intervention group
Intervention type: DRUG
Intervention: tolterodine
Description: oral
Study NCT03602508 — intervention group
Intervention type: DRUG
Intervention: oxybutynin
Description: oral
Study NCT03602508 — intervention group
Intervention type: DRUG
Intervention: trospium
Description: oral
Study NCT03602508 — intervention group
Intervention type: DRUG
Intervention: fesoterodine
Description: oral
Study NCT03602508 — intervention group
Intervention type: DRUG
Intervention: propiverine
Description: oral
Study NCT04021108 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab 240 MG
Description: Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
Study NCT00249860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a
Description: Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
Study NCT00249860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
Study NCT04021108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 MG
Description: Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
Study NCT00249860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin plus Interferon-beta-1a
Description: Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
Study NCT03837860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Placebo
Description: Oxycodone 20 mg plus placebo
Study NCT03837860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Risperidone
Description: Oxycodone (20mg) plus Risperidone (2 mg)
Study NCT03837860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Ziprasidone
Description: Oxycodone (20mg) plus Ziprasidone (80 mg)
Study NCT04995887 — intervention group
Intervention type: DEVICE
Intervention: Jada® System
Description: The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
Study NCT04173962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: administered 1 week prior to a laboratory-induced stress
Study NCT04173962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: administered 1 week prior to a laboratory-induced stress
Study NCT01547741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT01547741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT01547741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT01547741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT01090492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
Study NCT01090492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
Study NCT01090492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
Study NCT01090492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
Study NCT01090492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
Study NCT03216109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly telephone symptom assessment
Description: Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Care plans will be generated using an electronic management platform
Study NCT00368316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella conjugate vaccines
Description: Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
Study NCT00932217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: subcutaneous filgrastim administration
Study NCT00932217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenograstim
Description: subcutaneous lenograstim administration
Study NCT01856439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ProSavin
Description: Long term follow up of patients who received ProSavin in a previous study
Study NCT04647617 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Quantitative weight -bearing and report exercise sign data every weekly
Description: keep their normal live style
Study NCT04647617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative weight -bearing and report exercise sign data every weekly
Description: keep their normal live style
Study NCT02328820 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Percutaneous coronary intervention (PCI)
Description: For lesions with both FFR\<=0.8 and CFR\<2.0
Study NCT02328820 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optimal medical therapy (OMT)
Description: For lesions with FFR>0.8 or CFR>=2.0 or both
Study NCT05680792 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nitazoxanide
Description: 1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days
Study NCT05680792 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir/ritonavir
Description: 300/100 mg atazanavir/ritonavir tablets in the evening once daily, to be administered after meal for 5 days.
Study NCT01825837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 1800 mg once daily [Group 1 (Part II)]
Description: BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
Study NCT01825837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 900 mg once daily [Group 2 (Part II)]
Description: BIA 2-093 900 mg taken orally in the evening, for 2 weeks
Study NCT01825837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 300 mg once daily [Group 3 (Part II)]
Description: BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
Study NCT01825837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 900 mg (Part I)
Description: In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
Study NCT03795584 — intervention group
Intervention type: PROCEDURE
Intervention: sterile repositionable hemostasis clipping device close the large duodenal papilla incision
Description: After the bile duct stent was placed, the investigators can use sterile repositionable hemostasis clipping device to close large duodenal papilla incision at 11 o'clock on the duodenal papilla.
Study NCT02427984 — intervention group
Intervention type: OTHER
Intervention: Metal ions dosage and evaluation of local/systemic reaction
Description: Dosage of Chromium and Cobalt on several biological matrices deriving from each patients.~Determination of local/systemic reaction
Study NCT02427984 — intervention group
Intervention type: OTHER
Intervention: Noise registration and metal ions determination
Description: Dosage of Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of range of noise
Study NCT02427984 — intervention group
Intervention type: OTHER
Intervention: Metal ions dosage, evaluation of local/systemic reaction, noise registration
Description: Dosage of Chromium, Cobalt, Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of local/systemic reaction
Study NCT04030013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group education
Description: All patients of group 1 and 2 will receive intensive education for 3-4 months, then refreshment session every 3 months for 2 years. Initially, patient data will be collected through 3 types of forms: patient identification form, metabolic control parameters form and diabetes self-care scale questionnaire; then every 6 months metabolic parameters and diabetes self-care scale questionnaire will be reassessed.
Study NCT01090492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
Study NCT04178343 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: 1. the prescription of tomotherapy: whole brain radiation (WBRT) with 40Gy in 20 fractions and concurrent boost of 60Gy of the leptomeningeal metastases;~2. WBRT of 50Gy in 25 fractions, with dose limitation of hippocampus and brain stem; c.TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.~d. Some patients received intrathecal chemotherapy (MTX+AraC+Dex) based on the cytology of cerebrospinal fluid (CSF).
Study NCT01090492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
Study NCT01090492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
Study NCT03476109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomisation to omalizumab
Description: The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
Study NCT00945893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]
Description: 0.5 mL; (intranasal sprayer)
Study NCT00945893 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
Study NCT01768286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
Study NCT01768286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01796509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical, psychological, social
Description: After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
Study NCT03476109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomisation to mepolizumab
Description: The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
Study NCT01602120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
Study NCT01981330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aMSC
Description: aMSC injected into the vocal fold of the patient